How to Buy Cytomx Therapeutics Stock
Cytomx Therapeutics Inc
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer.
Cytomx Therapeutics stock last closed at $2.82, up 1.99% from the previous day, and has increased 46.11% in one year. It has overperformed other stocks in the Biotechnology industry by 0.67 percentage points. Cytomx Therapeutics stock is currently +43.88% from its 52-week low of $1.96, and -65.65% from its 52-week high of $8.21.
There are currently 217.9M CTMX shares outstanding. The market cap of CTMX is $614.48M. In the last 24 hours, 4.22M CTMX shares were traded.
How to Buy Cytomx Therapeutics Stock
Not sure how to invest in Cytomx Therapeutics stock? Here's how.
- Choose where to buy Cytomx Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy Cytomx Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your payment method and add your information.
- Analyze Cytomx Therapeutics stock: The Cytomx Therapeutics ticker symbol is CTMX. Is Cytomx Therapeutics stock a good investment? Should you buy shares of CTMX? How do CTMX's underlying business fundamentals look? Do top analysts think Cytomx Therapeutics is a good buy? Why has CTMX's stock price moved recently? (Hint: Our stock market research website can help you figure out if CTMX is a good stock to buy).
- Make your CTMX buy order: Decide if you will purchase CTMX shares at the current market price or use a limit order to purchase CTMX stock at a particular price.
- Get notifications regarding your CTMX investment: Create a watchlist to keep tabs on your position in Cytomx Therapeutics shares.
Step 1: Choose where to buy Cytomx Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy CTMX stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Energy, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've picked your brokerage, you need to fill out some personal info so you can buy CTMX today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start a new trading account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've finished signing up on one of the best stock trading apps, your next step is to transfer the money for your investment:
Watch the video below to see the process of depositing funds into your brokerage account.
Step 4: Analyze Cytomx Therapeutics stock
After you have selected the best place to buy Cytomx Therapeutics stock, it's very important to evaluate their stock before you invest, so you actually comprehend the risk and upside.
Cytomx Therapeutics shares quick numbers
Fundamentals of Cytomx Therapeutics
WallStreetZen was created to help average investors perform more in-depth fundamental analysis.
You can view all of the due diligence checks on CTMX's stock page.
Is CTMX stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge CTMX's true value.
Using relative valuations measures:
- CTMX could be undervalued based on its P/B ratio of 2.03x, relative to Biotechnology industry P/B ratio of 5.34x
You can do additional valuation research on CTMX's stock here.
CTMX Financial Overview
Positive Health Checks:
- CTMX has $331.81M in cash and short term investments. This is sufficient to cover its annual cash burn of $82.48M.
- Total CTMX debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the CTMX balance sheet.
- There are more short-term assets than long-term liabilities on the CTMX balance sheet.
- CTMX has a low debt to equity ratio of 0.26.
- CTMX has cash burn of 82482000. It has sufficient cash and short-term investments to cover this for at least one year.
Negative Health Checks:
- CTMX profit margin has gone down from 34% to -451.6% in the past year.
Do Wall Street analysts think it's a good time to buy Cytomx Therapeutics stock
Out of 6 sell side analysts who monitor CTMX, the consensus analyst rating on CTMX is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent CTMX Analyst Recommendations
Roger Song, a top 16% analyst from Jefferies maintains CTMX with a strong buy rating and raises their CTMX price target from $8.00 to $16.00, on Mar 18, 2026.
Jefferies's Roger Song raised their price target on (NASDAQ: CTMX) by 100% from $8 to $16 on 2026/03/18. The analyst maintained their Strong Buy rating on the stock.
Song said their price target hike was catalyzed by CytomX Therapeutics' announcement of "impressive" Phase 1 Varseta-M data in late-line metastatic colorectal cancer.
The analyst said the data opens a window for investors to take a position in a name holding "a rare ADC asset" capable of returning a $1B+ opportunity in third-line and later mCRC alone, with potential for $5B+ as it moves into first and second-line.
Earnings Report
Cytomx Therapeutics reported:
For Q4 2025:
- Loss per share of $0.22, which missed the Zacks Consensus Estimate of $(0.08) and Q4 2024’s $0.22.
- Revenue of $0.66M, which missed the Zacks Consensus Estimate by 90.98% and, by $38.09M.
For FY 2025:
- Loss per share of $0.15, compared to FY 2024’s $0.38.
- Revenue of $76.20M, down 44.8% Y/Y.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO Sean McCarthy, D.Phil. commented: “Today’s encouraging Varseta-M Phase 1 update underscores the program’s intentional design and broad potential in CRC as well as other EpCAM-expressing indications.
“CytomX’s top priority in 2026 is to align with the FDA on a registrational path for Varseta-M in late-line CRC.
“We also plan to accelerate Varseta-M combination studies to benefit CRC patients in earlier lines of treatment.
“Our continued and exciting progress with Varseta-M reinforces our leadership in the field of masking and CytomX’s ability to unlock true innovation.
“Our highly focused portfolio strategy is also illustrated by our second clinical program, CX-801.
“This masked version of Interferon-alpha-2b is being developed initially in advanced melanoma and, we believe, has the potential to become a new centerpiece of combination immunotherapy across multiple cancers.
“The CX-801 translational and biomarker data presented to date have been very encouraging, and we expect to share initial proof of concept data for the combination with KEYTRUDA® later this year.”
You can dig deeper into what analysts are forecasting on the Cytomx Therapeutics stock forecast page.
CTMX Technicals
CTMX Performance Metrics
Last year, CTMX revenue was $18.30M. Over the past 5 year, CTMX's revenue has gone up by -11.9% per year. This was slower than the Biotechnology industry average of 24.48%.
Find out more about CTMX's earnings and revenue performance here.
Latest Insiders Trades at CTMX
In the past 12 months, insiders at CTMX have sold more shares than they have bought.
Christopher Ogden, Chief Financial Officer of CTMX, was the latest CTMX insider to sell. They sold $4,953.20 worth of CTMX shares on Jun 15, 2026.
Dig into more about who owns CTMX shares here.
Can I rely on CTMX as an income stream?
No, Cytomx Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about CTMX
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Make your CTMX buy order
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly fine. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, use a limit order.
Click the Open Trade button and your broker will place the order.
If you require additional info about investing in stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your CTMX investment
Now that you own some shares in CTMX, you'll want to stay up-to-date on your new company.
Make a watchlist to get alerted to the latest events about your CTMX stock.
CTMX Feed
How to Buy Stock in Cytomx Therapeutics
To summarize, here are the 6 steps for buying Cytomx Therapeutics stock:
- Choose where to buy Cytomx Therapeutics stock
- Sign up for a brokerage account
- Deposit funds into your brokerage account
- Analyze Cytomx Therapeutics stock
- Make your CTMX buy order
- Get notifications regarding your CTMX investment
If you need a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep track of your new investment in Cytomx Therapeutics, click below.
More Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.